BRAINSTORM CELL THERAPUTC
BCLI
BCLI was delisted on the 17th of July, 2025.
38 hedge funds and large institutions have $10.5M invested in BRAINSTORM CELL THERAPUTC in 2019 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 13 increasing their positions, 4 reducing their positions, and 3 closing their positions.
225% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 4
67% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 3
20% more capital invested
Capital invested by funds: $8.69M → $10.5M (+$1.78M)
6% more funds holding
Funds holding: 36 → 38 (+2)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.01% less ownership
Funds ownership: 0.79% → 0.78% (-0.01%)
94% less call options, than puts
Call options by funds: $62K | Put options by funds: $1.06M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CIBC Private Wealth Group
Atlanta,
Georgia
|
+$199K |
| 2 |
DG
Delek Group
Herzliya,
Israel
|
+$161K |
| 3 |
Group One Trading
Chicago,
Illinois
|
+$139K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$83.3K |
| 5 |
Renaissance Technologies
New York
|
+$76.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$1.01M |
| 2 |
EMG
ETF Managers Group
Summit,
New Jersey
|
-$7.91K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$7K |
| 4 |
Bank of New York Mellon
New York
|
-$1.54K |
| 5 |
LPC
Loeb Partners Corp
New York
|
-$1.54K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AG
26
Advisor Group
Phoenix,
Arizona
| $20K | +$3.81K | +67 | +28% |
|
27
Simplex Trading
Chicago,
Illinois
| $19K | +$8.48K | +149 | +99% |
|
|
KPW
28
Kore Private Wealth
New York
| $17K | – | – | – |
|
29
First Manhattan
New York
| $15K | – | – | – |
|
30
Bank of Montreal
Toronto,
Ontario, Canada
| $9K | – | – | – |
|
|
IFAM
31
Institutional & Family Asset Management
Fort Collins,
Colorado
| $9K | – | – | – |
|
|
LPC
32
Loeb Partners Corp
New York
| $5K | -$1.54K | -27 | -25% |
|
|
ASN
33
Advisory Services Network
Atlanta,
Georgia
| $2K | – | – | – |
|
|
VFA
34
Valeo Financial Advisors
Carmel,
Indiana
| $2K | +$2.1K | +37 | New |
|
|
KFS
35
Kelly Financial Services
Braintree,
Massachusetts
| $1.45K | +$1.25K | +22 | New |
|
36
Citigroup
New York
| $1K | – | – | – |
|
37
US Bancorp
Minneapolis,
Minnesota
| $1K | – | – | – |
|
|
38
UBS Group
Zurich,
Switzerland
| – | -$7K | -130 | Closed |
|
|
FLI
39
Family Legacy Inc
Greenville,
South Carolina
| – | -$1K | -13 | Closed |
|
|
WOC
40
West Oak Capital
Westlake Village,
California
| – | -$533 | -10 | Closed |
|
BCLI Hedge Fund Activity: Q1 2019 in Review
38 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in BRAINSTORM CELL THERAPUTC (BCLI) for Q1 2019, worth a combined $10.5M — up 20% from $8.69M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new BCLI positions and 3 closed out — a net gain of 2 holders — while 13 added to existing stakes and 4 trimmed.
The largest buyer was CIBC Private Wealth Group, adding an estimated $199K. The largest seller was Sabby Management, cutting an estimated $1.01M.
- 38 institutional investors held BRAINSTORM CELL THERAPUTC (BCLI) as of Q1 2019, up from 36 in Q4 2018.
- Funds reported $10.5M of BRAINSTORM CELL THERAPUTC stock for Q1 2019, up 20% quarter-over-quarter.
- 5 funds opened new BRAINSTORM CELL THERAPUTC positions in Q1 2019 and 3 closed out, a net change of +2 holders.
- The largest BRAINSTORM CELL THERAPUTC buyer in Q1 2019 was CIBC Private Wealth Group, an estimated $199K added.
- The largest BRAINSTORM CELL THERAPUTC seller in Q1 2019 was Sabby Management, an estimated $1.01M sold.
Based on aggregated 13F filings for Q1 2019.